Specific Mutation Screening of TP53 Gene by Low-density DNA Microarray

Overview

Journal Nanotechnol Sci Appl

Publisher Dove Medical Press

Specialty Biotechnology

Date 2013 Nov 8

PMID 24198462

Authors

Angelica Rangel-Lopez

Alfonso Mendez-Tenorio

Kenneth L Beattie

Rogelio Maldonado

Patricia Mendoza

Guelaguetza Vazquez

Carlos Perez-Plasencia

Martha Sanchez

Guillermo Navarro

Mauricio Salcedo

Affiliations

Soon will be listed here.

Abstract

TP53 is the most commonly mutated gene in human cancers. Approximately 90% of mutations in this gene are localized between domains encoding exons 5 to 8. The aim of this investigation was to examine the ability of the low density DNA microarray with the assistance of double tandem hybridization platform to characterize TP53 mutational hotspots in exons 5, 7, and 8 of the TP53. Nineteen capture probes specific to each potential mutation site were designed to hybridize to specific site. Virtual hybridization was used to predict the stability of hybridization of each capture probe with the target. Thirty-three DNA samples from different sources were analyzed for mutants in these exons. A total of 32 codon substitutions were found by DNA sequencing. 24 of them a showed a perfect correlation with the hybridization pattern system and DNA sequencing analysis of the regions scanned. Although in this work we directed our attention to some of the most representative mutations of the TP53 gene, the results suggest that this microarray system proved to be a rapid, reliable, and effective method for screening all the mutations in TP53 gene.

References

Sanchez-Carbayo M . Use of high-throughput DNA microarrays to identify biomarkers for bladder cancer. Clin Chem. 2003; 49(1):23-31. DOI: 10.1373/49.1.23. View

Allawi H, SantaLucia Jr J . Nearest neighbor thermodynamic parameters for internal G.A mismatches in DNA. Biochemistry. 1998; 37(8):2170-9. DOI: 10.1021/bi9724873. View

Montesano R, Hollstein M, Hainaut P . Genetic alterations in esophageal cancer and their relevance to etiology and pathogenesis: a review. Int J Cancer. 1996; 69(3):225-35. DOI: 10.1002/(SICI)1097-0215(19960621)69:3<225::AID-IJC13>3.0.CO;2-6. View

Szymanska K, Hainaut P . TP53 and mutations in human cancer. Acta Biochim Pol. 2003; 50(1):231-8. View

Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian S, Hainaut P . Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat. 2007; 28(6):622-9. DOI: 10.1002/humu.20495. View

Prix L, Uciechowski P, Bockmann B, Giesing M, Schuetz A . Diagnostic biochip array for fast and sensitive detection of K-ras mutations in stool. Clin Chem. 2002; 48(3):428-35. View

Bergh J, Norberg T, Sjogren S, Lindgren A, Holmberg L . Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat Med. 1995; 1(10):1029-34. DOI: 10.1038/nm1095-1029. View

Allawi H, SantaLucia Jr J . Nearest-neighbor thermodynamics of internal A.C mismatches in DNA: sequence dependence and pH effects. Biochemistry. 1998; 37(26):9435-44. DOI: 10.1021/bi9803729. View

Relogio A, Schwager C, Richter A, Ansorge W, Valcarcel J . Optimization of oligonucleotide-based DNA microarrays. Nucleic Acids Res. 2002; 30(11):e51. PMC: 117213. DOI: 10.1093/nar/30.11.e51. View

10.

Allawi H, SantaLucia Jr J . Thermodynamics of internal C.T mismatches in DNA. Nucleic Acids Res. 1998; 26(11):2694-701. PMC: 147606. DOI: 10.1093/nar/26.11.2694. View

11.

Leroy K, Haioun C, Lepage E, Le Metayer N, Berger F, Labouyrie E . p53 gene mutations are associated with poor survival in low and low-intermediate risk diffuse large B-cell lymphomas. Ann Oncol. 2002; 13(7):1108-15. DOI: 10.1093/annonc/mdf185. View

12.

Velculescu V, El-Deiry W . Biological and clinical importance of the p53 tumor suppressor gene. Clin Chem. 1996; 42(6 Pt 1):858-68. View

13.

Lee I, Dombkowski A, Athey B . Guidelines for incorporating non-perfectly matched oligonucleotides into target-specific hybridization probes for a DNA microarray. Nucleic Acids Res. 2004; 32(2):681-90. PMC: 373323. DOI: 10.1093/nar/gkh196. View

14.

Miller L, Smeds J, George J, Vega V, Vergara L, Ploner A . An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A. 2005; 102(38):13550-5. PMC: 1197273. DOI: 10.1073/pnas.0506230102. View

15.

Tonisson N, Zernant J, Kurg A, Pavel H, Slavin G, Roomere H . Evaluating the arrayed primer extension resequencing assay of TP53 tumor suppressor gene. Proc Natl Acad Sci U S A. 2002; 99(8):5503-8. PMC: 122799. DOI: 10.1073/pnas.082100599. View

16.

Kirk G, Lesi O, Mendy M, Szymanska K, Whittle H, Goedert J . 249(ser) TP53 mutation in plasma DNA, hepatitis B viral infection, and risk of hepatocellular carcinoma. Oncogene. 2005; 24(38):5858-67. DOI: 10.1038/sj.onc.1208732. View

17.

Naef F, Lim D, Patil N, Magnasco M . DNA hybridization to mismatched templates: a chip study. Phys Rev E Stat Nonlin Soft Matter Phys. 2002; 65(4 Pt 1):040902. DOI: 10.1103/PhysRevE.65.040902. View

18.

Wu C, Carta R, Zhang L . Sequence dependence of cross-hybridization on short oligo microarrays. Nucleic Acids Res. 2005; 33(9):e84. PMC: 1140085. DOI: 10.1093/nar/gni082. View

19.

Halperin A, Buhot A, Zhulina E . Sensitivity, specificity, and the hybridization isotherms of DNA chips. Biophys J. 2004; 86(2):718-30. PMC: 1303922. DOI: 10.1016/S0006-3495(04)74150-8. View

20.

Martin A, Facchiano A, Cuff A, Hernandez-Boussard T, Olivier M, Hainaut P . Integrating mutation data and structural analysis of the TP53 tumor-suppressor protein. Hum Mutat. 2002; 19(2):149-64. DOI: 10.1002/humu.10032. View